Table 2 Multivariate analysis for Overall Survival for selected prognostic factors in NSCLC. A model was built for each variable of interest. All the variables listed at the upper file were included in the multivariabte Cox model, but the hazard ratios are shown only for those covariates that remained statistically significant during the forward stepwise analysis
Model 1 | |||||
Covariates | Age, Histology, Smoking status, ECOG PS, platinum treatment, comorbidity, BMI, weight loss, nodal status, pre-treatment fasting plasma glucose (FPG). | ||||
Variables in the equation | Parameter | Level | Hazard Ratio | 95% Confidence Interval | p-value |
Pre-treatment FPG | Continuous | 1.134 | 1.066–1.207 | < 0.001 | |
Platinum treatment | Carboplatin vs cisplatin | 1.657 | 1.121–2.451 | 0.011 | |
Comorbidity | Yes vs No | 1.508 | 1.020–2.229 | 0.039 | |
Model 2 | |||||
Covariates | Age, Histology, Smoking status, ECOG PS, platinum treatment, comorbidity, BMI, weight loss, nodal status, metabolic control groups. | ||||
Variables in the equation | Parameter | Level | Hazard Ratio | 95% Confidence Interval | p-value |
Metabolic control groups | No diabetes (reference group) | ||||
HbA1c ≤7 | 1.342 | 0.752–2.395 | 0.319 | ||
HbA1c 7.1–8.5 | 0.830 | 0.400–1.719 | 0.616 | ||
HbA1c > 8.5 | 4.534 | 2.210–9.301 | < 0.001 | ||
Platinum treatment | Carboplatin vs cisplatin | 1.946 | 1.264–2.996 | 0.002 | |
Comorbidity | Yes vs No | 1.720 | 1.125–2.632 | 0.012 | |
Model 3 | |||||
Covariates | Age, Histology, Smoking status, ECOG PS, platinum treatment, comorbidity, BMI, weight loss, nodal status, insulin treatment. | ||||
Variables in the equation | Parameter | Level | Hazard Ratio | 95% Confidence Interval | p-value |
Insulin treatment | Yes vs No | 3.225 | 1.906–5.456 | < 0.001 | |
Platinum treatment | Carboplatin vs cisplatin | 1.574 | 1.075–2.306 | 0.020 | |